Diazepam Slovakofarma

Diazepam Slovakofarma is a prescription oral medication that contains the benzodiazepine diazepam as its active ingredient. It is marketed in the European Union and is supplied in tablet form for systemic absorption. The product belongs to the anxiolytic therapeutic class and works by enhancing GABA activity at the GABA‑A receptor, providing sedative, anxiolytic, muscle‑relaxant, and anticonvulsant properties. It is intended for use under supervision and requires a prescription in jurisdictions.

Diazepam Slovakofarma is indicated for several central nervous system conditions where its anxiolytic, sedative, muscle‑relaxant, or anticonvulsant actions are beneficial.

- Management of anxiety disorders - Short‑term treatment of insomnia related to anxiety - Relief of muscle spasm and associated pain - Adjunct therapy for seizure disorders, including status epilepticus - Management of alcohol withdrawal syndrome

Side effects of diazepam may vary in frequency and severity; they are typically categorized as common or serious.

Common: - Drowsiness - Fatigue - Muscle weakness - Impaired coordination

Serious: - Respiratory depression - Severe hypotension - Paradoxical reactions such as agitation or aggression

Before prescribing or taking Diazepam Slovakofarma, clinicians and patients should consider several safety precautions.

- Classified as Pregnancy Category D; use only if benefits outweigh risks - Contraindicated in acute narrow‑angle glaucoma - Caution in patients with respiratory insufficiency or severe hepatic impairment - Avoid abrupt discontinuation to prevent withdrawal symptoms - Use with caution in elderly patients due to increased fall risk - Monitor for depression, suicidal ideation, or behavioral changes - Avoid use in individuals with a history of substance dependence

Diazepam can interact with other medicines, altering its effectiveness or increasing adverse effects.

Avoid: - Concurrent use with other CNS depressants (e.g., opioids, barbiturates, alcohol) may cause profound sedation or respiratory depression - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole) can increase diazepam plasma levels - CYP2C19 inhibitors (e.g., fluoxetine, omeprazole) may raise concentrations

Use with caution: - CNS stimulants (e.g., caffeine) may reduce sedative effect - Anticonvulsants such as phenytoin can lower diazepam levels - Certain antidepressants (e.g., SSRIs) may require monitoring for enhanced sedation